Advertisement
DHR vs RGEN
Which Stock Would AI Choose? Danaher (DHR) vs. Repligen (RGEN) Stock Comparison
Key Takeaways
- DHR provides diversified exposure across life sciences, diagnostics, and environmental solutions, supported by recent acquisitions such as Masimo.
- RGEN focuses on bioprocessing technologies, showing revenue growth of 15% in Q1 2026 with organic expansion of 11%.
- Recent market activity has seen DHR trade near $204 amid broader healthcare sector pressures and upcoming Q2 earnings.
- RGEN has demonstrated share price recovery in recent weeks following earlier volatility tied to growth guidance.
- DHR exhibits lower volatility with a beta around 0.79 compared to RGEN's beta of approximately 1.06.
- Both companies operate in the life sciences sector, with DHR offering greater scale and RGEN providing higher growth potential in bioprocessing.
Introduction
This comparison examines DHR and RGEN to highlight differences in business models, recent performance, and market positioning within the life sciences industry. The analysis draws on observable factors such as earnings trends, sector exposure, and relative momentum from recent market activity. Institutional investors, growth-oriented traders, and portfolio managers evaluating healthcare and biotechnology holdings may find the side-by-side assessment useful for understanding trade-offs in stability versus specialized growth opportunities.
DHR Overview and Recent Performance
DHR (Danaher Corporation) operates as a diversified science and technology company with segments in life sciences, diagnostics, and environmental solutions. Recent market activity shows the stock trading around $204 following periods of pressure linked to healthcare sector dynamics. The company completed the acquisition of Masimo, expanding its diagnostics capabilities, while preparing for Q2 earnings expected on July 21 with analyst estimates of $6.09 billion in revenue. Year-to-date returns have lagged broader indices amid cost considerations and macroeconomic influences on the sector.
RGEN Overview and Recent Performance
RGEN (Repligen Corporation) specializes in bioprocessing technologies and systems for the life sciences sector. In recent weeks, the stock has shown signs of stabilization near $148 after earlier volatility following earnings releases and guidance updates. Q1 2026 results featured revenue of $194 million, reflecting 15% reported growth and 11% organic growth, with adjusted EPS beating estimates. Management reiterated full-year organic revenue growth guidance of 9% to 13%, supported by initiatives including partnerships and portfolio optimization.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of high-performing AI trading bots from a much larger pool of hundreds available across thousands of tickers. Only those demonstrating the strongest alignment with prevailing market conditions, consistent performance metrics, and suitable trading styles earn placement in this section. Available bots span a wide range of strategies, timeframes, and statistical profiles, including varying win rates, drawdown levels, and ticker-specific focus areas. Users can explore detailed performance data and backtesting results to identify bots that match their objectives. For more information, visit Trending AI Robots.
Head-to-Head Comparison
DHR and RGEN differ markedly in scale and focus. DHR operates a broad portfolio across multiple life sciences verticals with substantial revenue and established M&A execution, contributing to relatively lower volatility. RGEN concentrates on bioprocessing, offering targeted exposure to biologics manufacturing trends but with higher sensitivity to sector-specific demand shifts. Recent momentum favors RGEN in organic growth metrics, while DHR benefits from diversification and analyst coverage reflecting more stable positioning. Risk factors include regulatory and integration challenges for DHR versus execution on growth targets for RGEN. Market sentiment reflects these contrasts, with DHR viewed as a defensive healthcare holding and RGEN as a higher-beta growth name.
Tickeron AI Verdict
Based on observable factors including trend consistency, lower volatility profile, and diversified catalysts, Tickeron’s AI models currently indicate a probabilistic preference for DHR in relative positioning. RGEN presents compelling growth attributes that could support outperformance under favorable bioprocessing demand scenarios. This assessment reflects current data patterns rather than guarantees of future results.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DHR is a Buy and RGEN is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DHR’s FA Score shows that 1 FA rating(s) are green whileRGEN’s FA Score has 0 green FA rating(s).
- DHR’s FA Score: 1 green, 4 red.
- RGEN’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DHR’s TA Score shows that 4 TA indicator(s) are bullish while RGEN’s TA Score has 4 bullish TA indicator(s).
- DHR’s TA Score: 4 bullish, 5 bearish.
- RGEN’s TA Score: 4 bullish, 4 bearish.
Price Growth
DHR (@Medical Specialties) experienced а +1.82% price change this week, while RGEN (@Pharmaceuticals: Other) price change was +6.86% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.40%. For the same industry, the average monthly price growth was -3.39%, and the average quarterly price growth was +6.80%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +5.03%. For the same industry, the average monthly price growth was +0.09%, and the average quarterly price growth was -1.71%.
Reported Earning Dates
DHR is expected to report earnings on Oct 27, 2026.
RGEN is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Medical Specialties (+0.40% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Pharmaceuticals: Other (+5.03% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| DHR | RGEN | DHR / RGEN | |
| Capitalization | 137B | 7.96B | 1,722% |
| EBITDA | 7.59B | 172M | 4,410% |
| Gain YTD | -14.468 | -13.945 | 104% |
| P/E Ratio | 34.76 | 193.16 | 18% |
| Revenue | 25.1B | 785M | 3,197% |
| Total Cash | 4.35B | 810M | 537% |
| Total Debt | 26.6B | 691M | 3,849% |
DHR | RGEN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 73 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 82 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 79 | 90 | |
PRICE GROWTH RATING 1..100 | 52 | 46 | |
P/E GROWTH RATING 1..100 | 70 | 100 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DHR's Valuation (8) in the Medical Specialties industry is significantly better than the same rating for RGEN (82) in the Biotechnology industry. This means that DHR’s stock grew significantly faster than RGEN’s over the last 12 months.
DHR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as RGEN (100) in the Biotechnology industry. This means that DHR’s stock grew similarly to RGEN’s over the last 12 months.
DHR's SMR Rating (79) in the Medical Specialties industry is in the same range as RGEN (90) in the Biotechnology industry. This means that DHR’s stock grew similarly to RGEN’s over the last 12 months.
RGEN's Price Growth Rating (46) in the Biotechnology industry is in the same range as DHR (52) in the Medical Specialties industry. This means that RGEN’s stock grew similarly to DHR’s over the last 12 months.
DHR's P/E Growth Rating (70) in the Medical Specialties industry is in the same range as RGEN (100) in the Biotechnology industry. This means that DHR’s stock grew similarly to RGEN’s over the last 12 months.
| DHR | RGEN | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 48% | 4 days ago 67% |
| Stochastic ODDS (%) | 3 days ago 64% | 3 days ago 72% |
| Momentum ODDS (%) | 3 days ago 62% | 3 days ago 75% |
| MACD ODDS (%) | 3 days ago 65% | 3 days ago 82% |
| TrendWeek ODDS (%) | 3 days ago 55% | 3 days ago 72% |
| TrendMonth ODDS (%) | 3 days ago 54% | 3 days ago 71% |
| Advances ODDS (%) | 6 days ago 54% | 18 days ago 74% |
| Declines ODDS (%) | 3 days ago 62% | 7 days ago 81% |
| BollingerBands ODDS (%) | 3 days ago 64% | 3 days ago 85% |
| Aroon ODDS (%) | 3 days ago 65% | 3 days ago 77% |
Advertisement
RGEN and
Correlation & Price change
A.I.dvisor indicates that over the last year, RGEN has been closely correlated with DHR. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if RGEN jumps, then DHR could also see price increases.
| Ticker / NAME | Correlation To RGEN | 1D Price Change % | ||
|---|---|---|---|---|
| RGEN | 100% | -1.80% | ||
| DHR - RGEN | 67% Closely correlated | -0.61% | ||
| A - RGEN | 65% Loosely correlated | -0.25% | ||
| BIO - RGEN | 60% Loosely correlated | -0.38% | ||
| MTD - RGEN | 59% Loosely correlated | +2.59% | ||
| TMO - RGEN | 58% Loosely correlated | -0.43% | ||
More | ||||